Filtered By:
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 855 results found since Jan 2013.
Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis
ConclusionsThis meta-analysis suggests that the HZV, but not antiviral treatment, decreases the odds of developing stroke.
Source: Frontiers in Neurology - May 17, 2023 Category: Neurology Source Type: research
Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Obstet Gynecol. 2023 May 11. doi: 10.1097/AOG.0000000000005241. Online ahead of print.ABSTRACTIn this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vac...
Source: Obstetrics and Gynecology - May 11, 2023 Category: OBGYN Authors: Malini B DeSilva Jacob Haapala Gabriela Vazquez-Benitez Thomas G Boyce Candace C Fuller Matthew F Daley Darios Getahun Simon J Hambidge Heather S Lipkind Allison L Naleway Jennifer C Nelson Kimberly K Vesco Eric S Weintraub Joshua T B Williams Ousseny Zer Source Type: research
Vaccines and Neurologic Complications; NIH Toolbox on iPad; The Dying Human Brain
(MedPage Today) -- A researcher from the National Institute of Neurological Disorders and Stroke reviewed challenges in determining neurologic complications of vaccines and what steps need to be taken. (Neurology)
Unawareness -- not heightened...
Source: MedPage Today Neurology - May 3, 2023 Category: Neurology Source Type: news
Progressive Central Artery Occlusion, Ophthalmic Artery Occlusion, and Hemispheric Intracranial Thrombosis after COVID-19 mRNA Vaccine Application: Case Report
Thromboembolic events as a result of COVID-19 mRNA vaccination are a rare, though life-threatening complication. In this case report, we describe a 40-year-old female patient who developed central retinal artery and ophthalmic artery occlusion progressing to intracranial thrombosis 3 weeks after vaccination with the Pfizer-BioNTech COVID-19 vaccine. Initially, she presented with progressive acute and painless unilateral vision loss in her left eye. Dilated fundoscopy of left eye showed macular whitening with sparing of the area of cilioretinal artery distribution. Labs revealed a normal erythrocyte sedimentation rate, C-re...
Source: Case Reports in Ophthalmology - April 18, 2023 Category: Opthalmology Source Type: research
Correlation Between Cardiovascular Protection and Influenza Vaccination
AbstractPurpose of ReviewInfluenza is the cause of millions of deaths yearly in the USA and globally. It presents a significant health burden in millions of people and is associated with chronic disease exacerbations including acute cardiovascular events such as myocardial infarction and stroke. We reviewed recent studies and a meta-analysis to assess the part that influenza vaccination plays in cardiovascular system protection.Recent FindingsA sizable study measured the effect of influenza vaccination on cardiovascular health and mortality. This retrospective observational study used the 2012 –2015 US National Inpatient...
Source: Current Cardiology Reports - April 14, 2023 Category: Cardiology Source Type: research
Patent Foramen Ovale-associated Stroke and COVID-19 Vaccination
Case –control studies have shown an association between patent foramen ovale (PFO) and cryptogenic stroke, which was observed particularly in patients younger than 55 years without conventional risk factors. The role of PFO closure in preventing stroke recurrence had been uncertain for many years, unt il four randomised clinical trials in 2017 and 2018 unequivocally demonstrated a benefit, with the number needed t...
Source: Radcliffe Cardiology - April 5, 2023 Category: Cardiology Authors: c242508f1d9059bc0f2aa9bdd5421ba2 Source Type: research
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
